Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Antiviral composition containing material involved in phosphatidylcholine snythesis pathway

a technology of phosphatidylcholine and antiviral composition, which is applied in the field of composition, can solve the problems of low effect of pirodavir, inability to develop therapeutic agents against i>rhinovirus /i>infection, and low pharmacokinetic value of pirodavir, so as to prevent or improve viral diseases

Inactive Publication Date: 2017-06-22
KOREA RES INST OF BIOSCI & BIOTECH
View PDF1 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention is about a substance that can stop viruses from multiplying. This substance can be used to make medicine and health foods to treat or prevent viral diseases. It can also be added to feeds to prevent or improve viral situations.

Problems solved by technology

However, therapeutic agents against rhinovirus infection have not yet been developed.
However, the tremacamra, a spray-type formulation, is disadvantageous in that it requires numerous administrations per day and that an effect thereof is low.
However, the pirodavir has a property that pharmacokinetic values are low even if it inhibits the proliferation of various rhinovirus serotypes.
Further, the pirodavir also has a property to be easily hydrolyzed, and thus cannot be progressed to be used as a therapeutic agent.
J Microbiol Immunol Infect 33(1):1-8), but has not yet been approved by the US Food and Drug Administration (USFDA) due to drug interaction, marginal efficacy, and production of virus resistance.
However, it is disadvantageous in that target RNAi needs to be prepared separately depending on more than 100 types of rhinoviruses
However, the ribavirin is known to exacerbate heart disease by inducing severe anemia and is disadvantageous in that it induces various side effects, such as fatigue, headache, etc.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antiviral composition containing material involved in phosphatidylcholine snythesis pathway
  • Antiviral composition containing material involved in phosphatidylcholine snythesis pathway
  • Antiviral composition containing material involved in phosphatidylcholine snythesis pathway

Examples

Experimental program
Comparison scheme
Effect test

example 1

Antiviral Activity Test Against Rhinovirus

[0088]HeLa cells (2×104 cells) were placed in each well of 96-well plates and cultured for 24 hours. After 24 hours, the culture supernatant of each well was removed, and then rhinovirus type 2, type 3, and type 5 solutions titrated with TCID50 were placed in each well. The virus used in the present invention was purchased from the American Type Culture Collection (ATCC). Each virus activity thereof was cultured and stored at −70° C. for use.

[0089]Ribavirin, which is a control group, cytidine triphosphate, CDP-choline, phosphatidylcholine, and adenosine triphosphate, which are experimental groups, were treated in each well in amounts of 0.1 μg / ml, 1 μg / ml, 10 μg / ml, and 100 μg / ml, respectively. Each compound was purchased from Sigma Corp.

[0090]The anti-proliferative ability against a virus was measured according to the methods described in Korean Patent No. 10-0682069. Specifically, after completion of the viral infection test, a 70% aceton...

example 2

Antiviral Activity Test Against Enterovirus

[0100]Vero cells (2×104 cells) were placed in each well of 96-well plates and cultured for 24 hours. After 24 hours, the culture supernatant of each well was removed, and then coxsackievirus type A solution or type B solution, which is a type of enterovirus, titrated with TCID50 was placed in each well. In addition, as shown in FIG. 6, choline, cytidine triphosphate, CDP-choline, and phosphatidylcholine were added thereto at concentrations of 0.1 μg / ml, 1μg / ml, 10 μg / ml, and 100 μg / ml. As a result, it was confirmed that the antiviral activity of cytidine triphosphate, CDP-choline, and phosphatidylcholine increased as the concentration thereof increased. Further, it was also confirmed that the antiviral activity of phosphatidylcholine was significantly remarkable at the concentration of 100 μg / ml compared to that of ribavirin, an antiviral agent used as the control group (Table 2).

TABLE 2Drug concentration (100 μg / mL)CoxsackievirusCoxsackie...

example 3

Inhibitory Activity of Viral RNA Production

[0103]In order to confirm mechanism of the composition of the present invention, which inhibits the necrosis of virus-infected cells, the following experiment was conducted.

[0104]In FIG. 8-A, HeLa cells were cultured in a 6-well plate, followed by infecting rhinovirus type 2 with TCID50. Thereafter, ribavirin, CDP-choline, phosphatidylcholine, ATP, and CTP were added to each well, and then RNA was respectively isolated from the cells in each well after 48 hours. cDNA was prepared using reverse transcriptase from the same amount of the extracted RNA, and beta-actin genes (300 bp) were amplified using a beta-actin-specific primer set. The result thereof is represented in FIG. 8-A, and it was confirmed that beta-actin genes in all wells were amplified in similar amounts.

[0105]In FIG. 8-B, rhinovirus genes (188 bp) were amplified using a rhinovirus-specific primer from cDNA previously prepared. The result thereof is represented in FIG. 8-B. The...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
sizeaaaaaaaaaa
diameteraaaaaaaaaa
pHaaaaaaaaaa
Login to View More

Abstract

The present invention relates to an antiviral composition comprising any one selected from the group consisting of chlorine, phosphocholine, cytidine triphosphate, CDP-choline, phosphorylcholine, and phosphatidylcholine. The antiviral composition is harmless to the human body and exhibits an excellent inhibitory effect on virus proliferation. Therefore, it can be applied to a pharmaceutical composition for preventing or treating viral diseases as well as a health functional food, a quasi-drug composition, and a feed composition for preventing or ameliorating viral diseases.

Description

TECHNICAL FIELD[0001]The present invention relates to a composition for inhibiting viral proliferation, comprising at least one substance involved in phosphatidylcholine synthesis pathway, a pharmaceutical composition for preventing or treating viral diseases comprising the same, and a health functional food composition, a quasi-drug composition, and a feed composition for preventing or ameliorating viral diseases.BACKGROUND ART[0002]Picornavirus is a positive single-stranded RNA virus with 7.2 Kb to 8.5 Kb, in which an RNA genome is only 7500 nt long. In addition, the virus is a very small globular non-enveloped virus with a size of approximately 22 nm to 30 nm, and is the oldest known virus. Rhinovirus, enterovirus, cardiovirus, aphthovirus, hepatovirus, etc. belong to picornavirus. [0003]At least 50% of cold-inducing pathogenic viruses are rhinovirus. However, therapeutic agents against rhinovirus infection have not yet been developed. As drugs that inhibit rhinoviruses, tremacam...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/7056A61K9/14A61K9/20A23L33/10A61K9/00A23L33/15A23L33/135A61K31/685A61K9/48
CPCA61K31/7056A61K31/685A61K9/14A61K9/20A23V2002/00A61K9/0056A23L33/15A23L33/135A23L33/10A61K9/48A61K9/205A61K9/4866A61K31/14A61K31/66A61K31/6615A61K31/706A61K31/7064A61K31/7068A23K10/16A23K10/22A23K10/30A23K10/33A23K20/163A23K20/174A23K20/189A23K20/20A23K20/26A23K50/10A23K50/20A23K50/40A23L33/115A61P31/00A61P31/12Y02P60/87Y02A50/30A23V2200/324A23V2250/1846A23V2250/304
Inventor KWON, DUR HANJANG, MI JINSONG, JAE HYOUNGENKHTAIVAN, GANSUKHOH, SEI RYANG
Owner KOREA RES INST OF BIOSCI & BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com